Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IMCR 
Immunocore Holdings Ltd (IMCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: IMCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $62.2
1 Year Target Price $62.2
| 8 | Strong Buy |
| 5 | Buy |
| 3 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.78% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.67B USD | Price to earnings Ratio - | 1Y Target Price 62.2 |
Price to earnings Ratio - | 1Y Target Price 62.2 | ||
Volume (30-day avg) 17 | Beta 0.8 | 52 Weeks Range 23.15 - 39.33 | Updated Date 10/26/2025 |
52 Weeks Range 23.15 - 39.33 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.7% | Operating Margin (TTM) -15.18% |
Management Effectiveness
Return on Assets (TTM) -1.69% | Return on Equity (TTM) -5.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1331812629 | Price to Sales(TTM) 4.68 |
Enterprise Value 1331812629 | Price to Sales(TTM) 4.68 | ||
Enterprise Value to Revenue 3.74 | Enterprise Value to EBITDA -45.82 | Shares Outstanding 50387068 | Shares Floating 37572629 |
Shares Outstanding 50387068 | Shares Floating 37572629 | ||
Percent Insiders 0.03 | Percent Institutions 98.17 |
Upturn AI SWOT
Immunocore Holdings Ltd
Company Overview
History and Background
Immunocore Holdings Ltd was founded in 1999 and is headquartered in Abingdon, UK. It is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAC molecules that are designed to redirect the human immune system to recognize and kill cancer cells.
Core Business Areas
- Oncology: Focuses on developing ImmTAC molecules for the treatment of various cancers, including melanoma, non-small cell lung cancer, and other solid tumors.
Leadership and Structure
Bahija Jallal serves as Chief Executive Officer. The company has a board of directors and operates with functional departments focused on research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Kimmtrak (tebentafusp): Kimmtrak is Immunocore's first commercial product, approved for the treatment of unresectable or metastatic uveal melanoma (mUM). It is the first and only therapy approved for this indication. While specific market share data is variable and evolving, Kimmtrak holds the dominant position in the mUM treatment landscape. Key competitors are traditional chemotherapy regimens and other investigational immunotherapies for solid tumors. Revenue from Kimmtrak continues to grow.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by the increasing prevalence of cancer and advances in cancer therapies. Immunotherapy is a major area of innovation, with TCR-based therapies representing a novel approach.
Positioning
Immunocore is a leader in the development of TCR bispecific immunotherapies. Kimmtrak's approval has established Immunocore as a commercial-stage company with a differentiated technology platform.
Total Addressable Market (TAM)
The TAM for Immunocore's oncology pipeline is significant. The global cancer immunotherapy market size was valued at USD 101.36 billion in 2023 and is projected to grow to USD 266.26 billion by 2032. Immunocore is positioned to capture a share of this expanding market with its ImmTAC technology and pipeline of novel cancer therapies.
Upturn SWOT Analysis
Strengths
- First-mover advantage in TCR bispecific immunotherapy
- Approved product (Kimmtrak) with commercial infrastructure
- Strong intellectual property portfolio
- Experienced management team
- Novel ImmTAC platform with broad applicability
Weaknesses
- Reliance on a single approved product
- High research and development costs
- Need for successful clinical trial outcomes for pipeline expansion
- Competition from established immunotherapy approaches
Opportunities
- Expansion of Kimmtrak to other indications
- Advancement of pipeline candidates through clinical development
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy companies
- Pricing and reimbursement pressures
- Patent challenges
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BMY
- NVS
Competitive Landscape
Immunocore is a pioneer in TCR bispecifics, but faces competition from established immunotherapy companies developing checkpoint inhibitors, cell therapies, and other cancer treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and Kimmtrak commercialization.
Future Projections: Future growth is dependent on the successful development and commercialization of pipeline candidates, as well as continued growth of Kimmtrak sales. Analyst projections are available from financial data providers.
Recent Initiatives: Recent strategic initiatives include clinical trial advancements for pipeline candidates and expansion of the commercial infrastructure.
Summary
Immunocore is a promising biotechnology company with a novel technology platform and a first-in-class product for uveal melanoma. Its strength lies in its innovative technology and commercialized product. However, its reliance on a single product and need for successful clinical trials pose risks. The company needs to carefully manage its resources and focus on expanding its pipeline and market reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunocore Holdings Ltd. Investor Relations, SEC Filings, Market Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunocore Holdings Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | CEO & Executive Director Dr. Bahija Jallal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 493 | Website https://www.immunocore.com |
Full time employees 493 | Website https://www.immunocore.com | ||
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.